255 related articles for article (PubMed ID: 27984850)
1. Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia.
van der Meer AC; Hanna LS
Clin Obes; 2017 Feb; 7(1):54-57. PubMed ID: 27984850
[TBL] [Abstract][Full Text] [Related]
2. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
Chin J; Konje JC; Hickey M
Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
[TBL] [Abstract][Full Text] [Related]
3. Malignant endometrial polyp in woman with the levonorgestrel intrauterine system - a case report.
Kuzel D; Mara M; Zizka Z; Koliba P; Dundr P; Fanta M
Gynecol Endocrinol; 2019 Feb; 35(2):112-114. PubMed ID: 30449212
[TBL] [Abstract][Full Text] [Related]
4. Advanced endometrial cancer following the insertion of the levonorgestrel-releasing intrauterine system in a 34-year-old woman: A case report.
Jiang J; Du H; Peng H
Contraception; 2020 Dec; 102(6):428-429. PubMed ID: 32860769
[TBL] [Abstract][Full Text] [Related]
5. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.
Kresowik J; Ryan GL; Van Voorhis BJ
Obstet Gynecol; 2008 Feb; 111(2 Pt 2):547-9. PubMed ID: 18239018
[TBL] [Abstract][Full Text] [Related]
6. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
[TBL] [Abstract][Full Text] [Related]
7. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
[TBL] [Abstract][Full Text] [Related]
8. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review.
Buttini MJ; Jordan SJ; Webb PM
Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):316-22. PubMed ID: 19566568
[TBL] [Abstract][Full Text] [Related]
9. Endometrioid adenocarcinoma after insertion of a levonorgestrel-releasing intrauterine system.
Flemming R; Sathiyathasan S; Jackson A
J Minim Invasive Gynecol; 2008; 15(6):771-3. PubMed ID: 18971148
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
[TBL] [Abstract][Full Text] [Related]
11. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review.
Wan YL; Holland C
Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273
[TBL] [Abstract][Full Text] [Related]
13. Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman.
Abu J; Brown L; Ireland D
Int J Gynecol Cancer; 2006; 16(3):1445-7. PubMed ID: 16803545
[TBL] [Abstract][Full Text] [Related]
14. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
Ewies AA; Alfhaily F
Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
[TBL] [Abstract][Full Text] [Related]
15. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
[TBL] [Abstract][Full Text] [Related]
16. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
Abu Hashim H; Ghayaty E; El Rakhawy M
Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
[TBL] [Abstract][Full Text] [Related]
17. Levonorgestrel-releasing intrauterine system versus systemic progestins in management of endometrial hyperplasia: A systemic review and meta-analysis.
Elassall GM; Sayed EG; Abdallah NA; El-Zohiry MM; Radwan AA; AlMahdy AM; Sedik AS; Elazeem HASA; Shazly SA
J Gynecol Obstet Hum Reprod; 2022 Oct; 51(8):102432. PubMed ID: 35760334
[TBL] [Abstract][Full Text] [Related]
18. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
Ørbo A; Arnes M; Vereide AB; Straume B
BJOG; 2016 Aug; 123(9):1512-9. PubMed ID: 26630538
[TBL] [Abstract][Full Text] [Related]
19. [Levonorgestrel-releasing intrauterine system Mirena® (Bayer) for the prevention and treatment of endometrial adenocarcinoma and the incidence of other malignancies in women].
Jóźwik M; Jóźwik M; Modzelewska B; Niewińska M; Jóźwik M
Ginekol Pol; 2015 Apr; 86(4):305-10. PubMed ID: 26117991
[TBL] [Abstract][Full Text] [Related]
20. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia.
El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S
Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
